Fixed-duration triplet therapy demonstrates efficacy for patients with relapsed/refractory chronic lymphocytic leukemia

Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care venetoclax plus rituximab therapy, according to interim data from the randomized, phase 3 BRUIN CLL-322 clinical trial.

Matthew Davids, MD, MMSc, chief of the Division of Lymphoma at Dana-Farber Cancer Institute, presented the results in the Late-Breaking Abstract session at the European Hematology Association 2026 Congress in Stockholm, Sweden, on June 14, 2026. ...